v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | IRCT20200413047063N2 |
Full text link
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
|
First author
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
|
Contact
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
soleimani.masoud@gmail.com |
Registration date
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
2021-04-14 |
Recruitment status
Last imported at : May 20, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
Completed |
Study design
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
RCT |
Allocation
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
Randomized |
Design
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
Parallel |
Masking
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
Open label |
Center
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
multi-center |
Study aim
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
Treatment |
Inclusion criteria
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
Confirmation of 2019-nCoV infection by RT-PCR Diagnosis of ARDS according to the Berlin definition of ARDS Requiring supplemental oxygen, PaO2/oxygen absorption concentration (FiO2) ≤ 300MMHG Pulmonary imaging shows that the focused progress > 50% in 24-48 hours Mild to Moderate 2019-nCoV pneumonia/ stay in the ICU <48 hours SOFA score between 2-3 point Pneumonia that is judged by chest radiograph or CT |
Exclusion criteria
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
Severe allergies or allergies after 1st injection to stem cell preparations and their components Patients with a malignant tumor, other serious systemic diseases, and psychosis Co-Infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory infection virus Patients with previous history of pulmonary embolism Liver or kidney SOFA score of more than 3 points; combined with other organ failure (need organ support), Stage 4 severe chronic kidney disease or requiring dialysis (i.e. estimated glomerular filtration rate (eGFR) < 30) Pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial pneumonia Continuous use of immunosuppressive agents or organ transplants in the past 6 months In vitro life support (ECMO, ECCO2R, RRT) Pregnant or lactating women Uncontrolled underlying disease Be thought by researchers to be inappropriate to participate in this clinical study (Expected deaths within 48 hours, uncontrolled infections) |
Number of arms
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
2 |
Funding
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
Omid Cell and Tissue center |
Inclusion age min
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
18 |
Inclusion age max
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
70 |
Countries
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
Iran |
Type of patients
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
Severe disease at enrollment |
Severity scale
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
6: Severe disease at enrollment |
Total sample size
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
50 |
primary outcome
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
Adverse events assesment |
Notes
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
|
Phase
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
Phase 1/Phase 2 |
Arms
Last imported at : April 15, 2021, 1 a.m. Source : Iranian Registry of Clinical Trials (IRCT) |
[{"arm_notes": "", "treatment_id": 788, "treatment_name": "Mesenchymal stem cells exosomes", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}] |